Evidence map›Paper›PMID 25266119›Full record

ArticleBMC pharmacology & toxicology2014

Open, single-blind, double-blind: which peer review process do you prefer?

Elizabeth C Moylan, Simon Harold, Ciaran O'Neill, Maria K Kowalczuk

Abstract readEditorial
In one paragraph

Article in BMC pharmacology & toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Effective Peer Review: Who, Where, or What?JID innovations : skin science from molecules to population health · 2022
    Article
  3. Article
  4. What Constitutes Authorship in the Social Sciences?Frontiers in research metrics and analytics · 2021
    Article
  5. Statement on Publication Ethics for Editors and Publishers.Journal of Korean medical science · 2016
    Review
  6. 'Scholarly peer reviewing': The art, its joys and woes.Indian journal of anaesthesia · 2015
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth C MoylanBioMed Central Ltd, 236 Gray's Inn Road, London WC1X 8HL, UK. elizabeth.moylan@biomedcentral.com.
Simon Harold
Ciaran O'Neill
Maria K Kowalczuk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BMC Pharmacology and Toxicology was created from the merger of two journals within the BMC series published by BioMed Central: BMC Pharmacology and BMC Clinical Pharmacology. BMC Pharmacology operated anonymous peer review whereas BMC Clinical Pharmacology operated a fully open peer review policy where the identity of the reviewers was known to the editors, authors and readers. The merged journal also adopted a fully open peer review policy. Two years on we discuss the views and experiences of our Editorial Board Members towards open peer review on this biomedical journal.

Indexed as

Peer Review, ResearchDouble-Blind MethodSingle-Blind Method

Identifiers

PMID25266119
PMCPMC4191873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.